Cargando…
Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET
OBJECTIVES: To assess the frequency and intensity of [(18)F]-prostate-specific membrane antigen (PSMA)-1007 axillary uptake in lymph nodes ipsilateral to COVID-19 vaccination with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) in patients with prostate cancer referred for oncological [(18)F]-PSMA...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Institute of Radiology.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364367/ https://www.ncbi.nlm.nih.gov/pubmed/36017171 http://dx.doi.org/10.1259/bjro.20210084 |
_version_ | 1784765132670238720 |
---|---|
author | Maurer, Alexander Schiesser, Helen Skawran, Stephan Gennari, Antonio G. Dittli, Manuel Burger, Irene A. Mader, Cäcilia Berger, Christoph Eberli, Daniel Huellner, Martin W. Messerli, Michael |
author_facet | Maurer, Alexander Schiesser, Helen Skawran, Stephan Gennari, Antonio G. Dittli, Manuel Burger, Irene A. Mader, Cäcilia Berger, Christoph Eberli, Daniel Huellner, Martin W. Messerli, Michael |
author_sort | Maurer, Alexander |
collection | PubMed |
description | OBJECTIVES: To assess the frequency and intensity of [(18)F]-prostate-specific membrane antigen (PSMA)-1007 axillary uptake in lymph nodes ipsilateral to COVID-19 vaccination with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) in patients with prostate cancer referred for oncological [(18)F]-PSMA positron emission tomography (PET)/CT or PET/MR imaging. METHODS: 126 patients undergoing [(18)F]-PSMA PET/CT or PET/MR imaging were retrospectively included. [(18)F]-PSMA activity (maximum standardized uptake value) of ipsilateral axillary lymph nodes was measured and compared with the non-vaccinated contralateral side and with a non-vaccinated negative control group. [(18)F]-PSMA active lymph node metastases were measured to serve as quantitative reference. RESULTS: There was a significant difference in maximum standardized uptake value in ipsilateral and compared to contralateral axillary lymph nodes in the vaccination group (n = 63, p < 0.001) and no such difference in the non-vaccinated control group (n = 63, p = 0.379). Vaccinated patients showed mildly increased axillary lymph node [(18)F]-PSMA uptake as compared to non-vaccinated patients (p = 0.03). [(18)F]-PSMA activity of of lymph node metastases was significantly higher (p < 0.001) compared to axillary lymph nodes of vaccinated patients. CONCLUSION: Our data suggest mildly increased [(18)F]-PSMA uptake after COVID-19 vaccination in ipsilateral axillary lymph nodes. However, given the significantly higher [(18)F]-PSMA uptake of prostatic lymph node metastases compared to “reactive” nodes after COVID-19 vaccination, no therapeutic and diagnostic dilemma is to be expected. ADVANCES IN KNOWLEDGE: No specific preparations or precautions (e.g. adaption of vaccination scheduling) need to be undertaken in patients undergoing [(18)F]-PSMA PET imaging after COVID-19 vaccination. |
format | Online Article Text |
id | pubmed-9364367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The British Institute of Radiology. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93643672022-08-24 Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET Maurer, Alexander Schiesser, Helen Skawran, Stephan Gennari, Antonio G. Dittli, Manuel Burger, Irene A. Mader, Cäcilia Berger, Christoph Eberli, Daniel Huellner, Martin W. Messerli, Michael BJR Open Original Research OBJECTIVES: To assess the frequency and intensity of [(18)F]-prostate-specific membrane antigen (PSMA)-1007 axillary uptake in lymph nodes ipsilateral to COVID-19 vaccination with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) in patients with prostate cancer referred for oncological [(18)F]-PSMA positron emission tomography (PET)/CT or PET/MR imaging. METHODS: 126 patients undergoing [(18)F]-PSMA PET/CT or PET/MR imaging were retrospectively included. [(18)F]-PSMA activity (maximum standardized uptake value) of ipsilateral axillary lymph nodes was measured and compared with the non-vaccinated contralateral side and with a non-vaccinated negative control group. [(18)F]-PSMA active lymph node metastases were measured to serve as quantitative reference. RESULTS: There was a significant difference in maximum standardized uptake value in ipsilateral and compared to contralateral axillary lymph nodes in the vaccination group (n = 63, p < 0.001) and no such difference in the non-vaccinated control group (n = 63, p = 0.379). Vaccinated patients showed mildly increased axillary lymph node [(18)F]-PSMA uptake as compared to non-vaccinated patients (p = 0.03). [(18)F]-PSMA activity of of lymph node metastases was significantly higher (p < 0.001) compared to axillary lymph nodes of vaccinated patients. CONCLUSION: Our data suggest mildly increased [(18)F]-PSMA uptake after COVID-19 vaccination in ipsilateral axillary lymph nodes. However, given the significantly higher [(18)F]-PSMA uptake of prostatic lymph node metastases compared to “reactive” nodes after COVID-19 vaccination, no therapeutic and diagnostic dilemma is to be expected. ADVANCES IN KNOWLEDGE: No specific preparations or precautions (e.g. adaption of vaccination scheduling) need to be undertaken in patients undergoing [(18)F]-PSMA PET imaging after COVID-19 vaccination. The British Institute of Radiology. 2022-09-09 /pmc/articles/PMC9364367/ /pubmed/36017171 http://dx.doi.org/10.1259/bjro.20210084 Text en © 2022 The Authors. Published by the British Institute of Radiology https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Original Research Maurer, Alexander Schiesser, Helen Skawran, Stephan Gennari, Antonio G. Dittli, Manuel Burger, Irene A. Mader, Cäcilia Berger, Christoph Eberli, Daniel Huellner, Martin W. Messerli, Michael Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET |
title | Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET |
title_full | Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET |
title_fullStr | Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET |
title_full_unstemmed | Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET |
title_short | Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET |
title_sort | frequency and intensity of [(18)f]-psma-1007 uptake after covid-19 vaccination in clinical pet |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364367/ https://www.ncbi.nlm.nih.gov/pubmed/36017171 http://dx.doi.org/10.1259/bjro.20210084 |
work_keys_str_mv | AT maureralexander frequencyandintensityof18fpsma1007uptakeaftercovid19vaccinationinclinicalpet AT schiesserhelen frequencyandintensityof18fpsma1007uptakeaftercovid19vaccinationinclinicalpet AT skawranstephan frequencyandintensityof18fpsma1007uptakeaftercovid19vaccinationinclinicalpet AT gennariantoniog frequencyandintensityof18fpsma1007uptakeaftercovid19vaccinationinclinicalpet AT dittlimanuel frequencyandintensityof18fpsma1007uptakeaftercovid19vaccinationinclinicalpet AT burgerirenea frequencyandintensityof18fpsma1007uptakeaftercovid19vaccinationinclinicalpet AT madercacilia frequencyandintensityof18fpsma1007uptakeaftercovid19vaccinationinclinicalpet AT bergerchristoph frequencyandintensityof18fpsma1007uptakeaftercovid19vaccinationinclinicalpet AT eberlidaniel frequencyandintensityof18fpsma1007uptakeaftercovid19vaccinationinclinicalpet AT huellnermartinw frequencyandintensityof18fpsma1007uptakeaftercovid19vaccinationinclinicalpet AT messerlimichael frequencyandintensityof18fpsma1007uptakeaftercovid19vaccinationinclinicalpet |